Rasna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2019
January 14, 2020 at 03:30 am IST
Share
Rasna Therapeutics, Inc. announced earnings results for the full year ended September 30, 2019. For the full year, the company announced operating loss was USD 915,170 compared to USD 4.067 million a year ago. Net loss was USD 936,380 compared to USD 4.076 million a year ago. Basic loss per share was USD 0.01 compared to USD 0.06 a year ago.
Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.
ACTAVIA LIFE SCIENCES, INC. 
